Articles tagged with Chemotherapy
The dose-adjusted (DA) EPOCH-R regimen was found to be highly effective and better tolerated than standard chemotherapy for adults with Burkitt lymphoma. The treatment was effective across age groups, including patients in their 70s and 80s, and regardless of HIV status.
Patients with germline or somatic mutations in DNA repair genes showed better clinical outcomes after platinum-based chemotherapy. These mutations were found in genes such as BRCA1, BRCA2, and PALB2, which are involved in a form of DNA repair known as homologous recombination.
Researchers identified two novel biomarkers, PDL1/CD274 copy number alteration and PD-L1 combined positive score, that correlate with improved outcomes in patients with metastatic breast cancer treated with immunotherapy. These biomarkers may help identify patients most likely to benefit from this treatment.
Researchers at Kazan Federal University have developed new in vitro test systems for selecting effective antitumor drugs, which take into account the complex interactions between tumor cells and healthy tissue. The new models aim to improve primary screening of substances with antitumor activity.
Researchers have developed a new method to stabilize liposomes using nanobowls, which improves the delivery of chemotherapy drugs to cancer cells. The nanobowl-stabilized liposomes showed reduced leakage and increased efficacy in treating metastatic breast tumors in mice.
A research team at Pohang University of Science & Technology has developed an integrative cancer therapy using adoptive natural killer cell therapy and chemotherapy. The new method enhances the effectiveness of cell therapy in treating solid cancers by selectively releasing anticancer drugs, reducing side effects.
Researchers at Waseda University have successfully developed a method for the total synthesis of cotylenin A, a plant growth regulator with promising bioactivity as an anti-cancer agent. The new method allows for the production of a stable and effective anticancer drug without the side effects associated with traditional treatments.
Women who watched Disney movies during chemotherapy experienced improved measures of quality of life compared to those who did not watch the movies. The study found that Disney movie watching had a positive impact on emotional well-being and stress levels in these patients.
A new method uses CAR-T therapy to eliminate leukemia stem cells and blood stem cells selectively, sparing mature blood cells and other tissues. The treatment is achieved through genetic modification of immune cells, which then target and destroy only the leukemic stem cells.
A clinical trial found that olanzapine significantly improved patient quality of life by reducing nausea and vomiting scores. The study showed that patients who received olanzapine reported less vomiting, better appetite, and better well-being compared to those who received a placebo.
Researchers developed a new conjugated drug, Nav-Gal, that selectively removes senescent cells, minimizing harm to healthy cells and reducing toxicity. The use of this compound in combination with chemotherapy may be a promising strategy for treating cancer.
A new study led by Yale Cancer Center researchers shows that immunotherapy prior to surgery can increase the rate of complete eradication of high-risk HER2-negative breast cancer from the breast and lymph nodes. The treatment combination of durvalumab, a checkpoint inhibitor, with chemotherapy resulted in a higher pCR rate compared to ...
Dexrazoxane has been shown to preserve cardiac function and reduce risk of severe cardiac events in pediatric patients undergoing chemotherapy for acute myeloid leukemia (AML). The study suggests dexrazoxane should be considered for cardioprotection in all pediatric patients undergoing standard chemotherapy for AML.
The Phase III EMBRACA trial found talazoparib improved patient-reported quality-of-life measures and had a tolerable safety profile in patients with metastatic HER2-negative breast cancer and BRCA1/2 mutations. However, the study did not demonstrate a statistically significant overall survival benefit due to subsequent treatments.
Researchers have discovered a new approach to overcome chemotherapy resistance in clear cell ovarian cancer by using low doses of 2-deoxy-D-glucose. The treatment has shown significant improvement in laboratory models and is expected to be safer for patients with reduced side effects.
A study published in Nature found that glioma patients with hypermutated tumor cells did not benefit from checkpoint blocker treatments. The researchers suggest that approaches increasing cytotoxic lymphocyte infiltration may improve immunotherapy response in gliomas.
The TAILORx trial found that women on hormone therapy also experienced cognitive decline, which leveled off over time. Cognitive function did not return to pre-treatment levels in either group, and hormone therapy may play a role in this impairment.
A study led by Washington State University researchers found that inhibiting the FOXO1 protein can protect the heart from cell death and atrophy caused by chemotherapy drugs like doxorubicin. This breakthrough discovery may lead to promising new treatment strategies or drugs that combine a FOXO1 inhibitor with doxorubicin.
A study published in Neuro-Oncology Advances suggests that chemotherapy can be effective against diffuse intrinsic pontine glioma (DIPG), a devastating childhood brain cancer. Researchers found that the medicine reaches DIPG tissue in good quantities, offering new hope for treatment.
A new case study using 5 head and neck squamous cell carcinoma cell lines shows improved drug screening through morphology and dead cell readouts. The research aims to enhance the value of cancer drug discovery and development success rates.
A recent study found that older cancer patients taking 15 or more medications prior to chemotherapy treatment had a 114% increase in hospitalization rates. The researchers also identified similar increases in breast and prostate cancer patients, with median medication counts of 6, 10, and 11 therapies respectively.
Combining therapeutic HPV vaccine ISA101 with chemotherapy drugs carboplatin and paclitaxel may extend survival in patients with advanced cervical cancer. The vaccine was well-tolerated, reducing suppressive myeloid cells to better stimulate T cell responses.
Researchers developed a microRNA-based signature that predicts local-regional failure and overall survival in patients with pancreatic cancer. The four-miRNA risk score provides prognostic information for clinical outcomes after surgical resection.
Researchers found that pairing Abraxane with Intralipid enhances tumor-killing macrophages, reducing cancer growth and protecting organs from damage. The combination also decreases the amount of expensive drugs needed for treatment.
A new imaging technique allows researchers to study 3D printed brain tumors in unprecedented detail, revealing how treatments affect complex tumor cells. This method provides a more accurate evaluation of drug effectiveness than traditional methods, which could lead to improved treatment outcomes for patients with glioblastomas.
A new trial has found that chemotherapy after surgery significantly reduces the risk of rare kidney cancer returning. The treatment has been shown to increase survival rates by over half, with 71% of patients living cancer-free for three years or more.
Yong Lu and David Soto-Pantoja receive grants to study immunotherapy and cardiotoxicity, aiming to improve cancer treatment outcomes and prevent heart disease. Their research could lead to new approaches in combating metastatic and treatment-resistant cancers.
Researchers at CNIO propose a novel approach using CDK4/6 inhibitors after chemotherapy to prevent tumor cells from resisting treatments. This strategy shows promising results in preventing tumor growth and death in mice with pancreatic adenocarcinoma, suggesting new avenues for improving cancer treatment.
The study found that patients whose breast cancer was completely eradicated by chemotherapy had a higher proportion of DNA mutational 'signature 3', indicating defects in DNA repair. This signature is associated with genes like BRCA, which could help doctors predict patient response to neoadjuvant chemotherapy.
A team of NUS researchers identified a novel protein S1P2 that can protect nerve cells from damage and pain when activated with a drug-like compound. This discovery holds promise for the prevention and treatment of chemotherapy-induced neuropathy, as well as other forms of neuropathy.
Researchers at Hackensack Meridian Health's CDI laboratory have made a breakthrough in treating blood cancers, specifically leukemia. They identified a novel protein called Stem Cell Growth Factor Alpha (SCGFa), which has shown promise in preserving vascular function and promoting hematopoietic recovery following chemotherapy.
Professor Lillian Siu receives TAT 2020 Honorary Award for her contributions to early drug development and phase I trials in head and neck malignancies. She advances the field of cancer drug development with innovative clinical trial designs and methodologies.
Researchers at KAIST have discovered mechanisms that fuel a 'domino effect' in cancer drug resistance, enabling failed responses to paclitaxel to speed up the evolution of resistance to other drugs. The study suggests a new strategy for improving second-line cancer treatment.
A type of micro RNA known as MIR1249 plays a key role in allowing bile duct cancers to resist chemotherapy. The researchers hope that targeting this molecule could make chemotherapy more effective.
Researchers at Mayo Clinic have discovered a method to make tumor cells more responsive to immunotherapy. By promoting genetic mutations in tumor cells, they found that these cells become vulnerable to immune system attacks. The approach showed promise across different types of tumors and patient genomes.
A University of Colorado Cancer Center study found that patients with locally advanced rectal cancer who received lower-than-recommended doses of neoadjuvant chemotherapy experienced a complete response and tumor shrinkage similar to those receiving the full dose.
A pilot study conducted by INRS researchers highlights the effect of chemotherapy on male fertility before and after puberty. The study found that all patients were at higher risk of infertility due to low sperm production, regardless of age at diagnosis.
A study by the Broad Institute of MIT and Harvard uncovered nearly 50 non-oncology drugs that can kill cancer cells, including those for diabetes, inflammation, and arthritis. The researchers identified novel drug mechanisms and targets, suggesting a possible way to accelerate the development of new cancer drugs.
Researchers developed a novel cryogel vaccine that primes the immune system to attack and eliminate acute myeloid leukemia cells in mice. The vaccine successfully protected against disease recurrence when combined with chemotherapy.
A new clinical trial has shown that giving men one cycle of chemotherapy is as effective at preventing testicular cancer from coming back as two cycles. This reduction in chemotherapy dosage lowered debilitating side effects, improving patients' quality of life.
Researchers at IKBFU identified spirocycles as a building block of organic molecules with potential for medical chemistry development. These naturally occurring compounds, such as artemisinin, exhibit biocompatibility and have inspired the synthesis of new medicinal compounds.
A new study led by Christine B. Ambrosone found that breast cancer patients taking antioxidants during chemotherapy had a 41% increased risk of disease recurrence and a similar but weaker risk of death. Patients using vitamin B12, iron, and omega-3 fatty acid supplements also showed poorer outcomes.
A Mayo Clinic study of 5,540 patients with metastatic colorectal cancer found that maintenance chemotherapy after initial treatment is more beneficial for patients whose disease is under control. The preferred regimen is fluoropyrimidine with or without bevacizumab, according to the analysis.
A metabolic inhibitor called OSI-027 induces catastrophic macropinocytosis in human cancer cells, reducing tumor growth when combined with chemotherapy. The study suggests that targeting the mTOR pathway may be an effective approach to treat drug-resistant cancers.
Salk researchers found that mitochondria trigger molecular alarms when cells are stressed, which can lead to increased resistance to chemotherapy. This discovery may pave the way for new cancer treatments that target mitochondrial stress.
Researchers found that women who used ibuprofen or naproxen had a 40% reduced breast cancer risk, while aspirin use offered no benefit. Young women with HER2-positive breast cancer may preserve fertility by choosing less intensive chemotherapy regimens.
Blinatumomab treatment demonstrates longer survival, fewer severe side effects, and higher undetectable residual disease rates compared to standard chemotherapy for children with high- or intermediate-risk B-cell acute lymphoblastic leukemia. The study shows promising results as a bridge to curative bone marrow transplant.
A new combination therapy of lower-dose chemotherapy and monoclonal antibodies has shown a 98% response rate in older patients with newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia. The three-year survival rate was 54%, with 30 patients in complete remission without signs of minimal residual disease.
A study by Dana-Farber researchers suggests that adding venetoclax to a reduced-intensity drug regimen prior to stem cell transplant can increase the chances of transplant success. The treatment has been found to be safe and does not impair donor cells' ability to engraft in recipients.
Researchers at the University of Cincinnati developed a new treatment for glioblastoma multiforme using coaxial electrospinning, which delivers a potent dose of medicine immediately or over time. The treatment improved survival rates in three separate animal trials and holds promise for other types of cancer.
Researchers have created a new technique to deliver chemotherapy directly to malignant cells, bypassing healthy ones. This discovery could allow doctors to reduce chemo doses and alleviate side effects, improving treatment outcomes.
A study published in SPIE Journal of Biomedical Optics found that diffuse reflectance spectroscopy can reliably discriminate between healthy tissue and tumor tissue, regardless of neoadjuvant chemotherapy status. The technique's feasibility for tumor-margin assessment during breast-conserving surgery has been demonstrated.
The study found that API-5 is overexpressed in chemoresistant TNBC, associated with increased micro-vessel density and enhanced cell survival. A peptide targeting API-5 shows promise as an innovative treatment option for this aggressive cancer type.
Researchers have developed 'combo' nanoplatforms using graphene oxide and reduced graphene oxide to enhance chemotherapy therapy. These nanocarriers can target tumors and improve drug delivery, reducing side effects on normal cells/tissues.
Scientists have characterised genetic alterations caused by six cancer therapies, revealing 'mutational footprints' that can help optimize treatment efficacy and minimize side effects. The study provides a new understanding of the relationship between therapy-induced mutations and long-term side effects.
Researchers discovered that SNAP, a nitric oxide donor, overcomes TMZ resistance in glioblastoma multiforme (GBM) cells by reducing MGMT protein stability. This finding offers a potential strategy to improve treatment outcomes for patients with GBM.
A new technique called ELeCt uses drug-loaded nanoparticles bound to circulating red blood cells to inhibit lung cancer metastasis with tenfold greater success than free-floating nanoparticles. The research has shown improved survival rates and reduced side effects in mice with lung cancer, making it a promising clinical treatment.
Researchers at the University of Texas MD Anderson Cancer Center found that secondary tumor-reduction surgery followed by chemotherapy did not result in longer survival than chemotherapy alone. The study involved 240 patients with platinum-sensitive recurrent ovarian cancer and showed that complete tumor resection was associated with i...
Researchers found that API-5 was overexpressed in endothelial cells of patients with chemoresistant TNBC, associated with increased micro-vessel density. API-5 promotes cell survival and cancer growth by inhibiting apoptosis.
A study in mice shows that chemotherapy affects gut bacteria, inflammation, and cognitive problems. Researchers found correlations between changes in the gut microbiome and brain inflammation, which could lead to new interventions for cancer patients.